<DOC>
	<DOCNO>NCT00038987</DOCNO>
	<brief_summary>To define safety vaccination APSV determine reactogenicity vaccine development expect un-expected adverse event associate vaccination . To assess proportion individual respond vaccination `` take '' ( form visible lesion injection site ) 6 8 day vaccination .</brief_summary>
	<brief_title>Vaccinia Virus Vaccine ( APSV ) Vaccinia- Naive Subjects : PILOT</brief_title>
	<detailed_description>The study four-center , randomize , dose find trial evaluate safety , preliminary efficacy , immunogenicity Aventis Pasteur smallpox vaccine ( APSV ) healthy , vaccinia-naive adult . Four concentration APSV , derive 2 lot vaccine , test ; range 10 ( exponent 6 pfu per ml ) 10 ( exponent 7.5 pfu per ml ) . Four concentration Dryvax ( range 10 exp 6 per ml 10 exp 8 per ml ) evaluate positive control . This study design assess feasibility use APSV dilution APSV emergency vaccination scenario . The study conduct two phase . The initial phase consist single-center , randomize , open-label study 45 subject evaluate safety approximate take rate undiluted APSV ( two lot APSV plus Dryvax control arm : n=15 per arm ) . A 14 day post vaccination safety follow-up complete subject vaccinate initial phase prior initiation second phase study additional 285 subject . All subject follow 56 day post vaccination clinic visit day 180 stage 1 subject follow-up phone call day 180 stage 2 subject . The expansion phase study conduct three additional site .</detailed_description>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>INCLUSION CRITERIA : Age : 1832 ( Volunteers 32 year age include since usually vaccinianaive . ) Children exclude due concern safety , include autoinoculation . Acceptable medical history screen evaluation form brief assessment . Negative urine pregnancy test woman . Negative history smallpox vaccination . Negative ELISA HIV negative Western blot volunteer positive ELISA participate HIV vaccine trial . Availability followup plan duration study ( 6 month ) . Note : Stage 1 clinic visit Day 180+/15 day , Stage 2 phone call Day 180 +/ 15 day . If volunteer female , agree use acceptable contraception become pregnant duration study . Willing sign inform consent . Adequate renal function define serum creatinine 1.5 mg/dL , urine protein &lt; 100 mg/dL negative proteinuria , calculate creatinine clearance &gt; 55 mL/min base follow formula : For male ( ( 140 minus age year ) x weight kg ) /72 x serum creatinine ) . For female : 0.85 x ( ( 140 minus age year ) x weight kg ) /72 x serum creatinine ) . Note : Renal function measure ensure subject could meet criterion use cidofovir need . EXCLUSION CRITERIA : History immunodeficiency . Serology positive HIV , hepatitis B , hepatitis C screen visit . Known suspected impairment immunologic function include , limited , clinically significant liver disease . Diabetes mellitus . Moderate severe kidney impairment . Malignancy , squamous cell basal cell skin cancer . Autoimmune disease . Use immunosuppressive medication . Corticosteroid nasal spray permissible . Medical psychiatric condition occupational responsibility preclude subject compliance protocol . History `` illegal '' injection drug use . Live attenuate vaccine within 60 day study . Use experimental agent within 30 day prior study . Any history vaccination vaccinia vectored pox vectored experimental vaccine . Typical vaccinia scar without known history vaccination . History smallpox vaccination . Acute febrile illness day vaccination . Pregnant lactating woman . Eczema degree history eczema . History exfoliative skin disorders/conditions . Any acute skin disorder large magnitude , e.g. , laceration require suture , burn great 2x2 cm . Receipt blood product immunoglobulin past 6 month . Household contacts/sexual contact , occupational exposure ( minimal contact ) , people follow : pregnancy , &lt; 12 month age , eczema history eczema , previously list skin disorders/conditions , immunodeficiency disease use immunosuppressive medication . Allergies component vaccine ( e.g . polymyxin B sulfate , dihydrostreptomycin sulfate , chlortetracycline hydrochloride , neomycin sulfate ) . Allergies know component diluent . Allergies know component VIG , i.e. , thimerosal previous allergic reaction immunoglobulin . Allergies cidofovir probenicid . Blood donation within past 55 day ( stage 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>32 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>Smallpox</keyword>
	<keyword>APSV</keyword>
	<keyword>Aventis Pasteur Smallpox Vaccine</keyword>
	<keyword>vaccinia-naive</keyword>
</DOC>